JW Lifescience

JW생명과학 · 234080

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$129.1M (₩178.1B)

Overview

JW Lifescience makes intravenous fluids, the bags of liquid solution administered directly into a patient's bloodstream in hospitals and clinics.

Its products are prescription-only medicines supplied to healthcare providers. The company's entire business is focused on this single product category, intravenous fluids, making it a specialist rather than a broad pharmaceutical company. It is listed on KOSPI, South Korea's main stock exchange.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$186.8M

▲ +15.9% YoY

Operating profit · FY2025

US$24.1M

▼ −7.3% YoY

Net income · FY2025

US$20.7M

▼ −35.0% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$149.9M(₩206.9B)	US$161.2M(₩222.5B)	US$186.8M(₩257.8B)
Operating profit	US$22.4M(₩30.9B)	US$26M(₩35.9B)	US$24.1M(₩33.2B)
Net income	US$20.4M(₩28.1B)	US$31.9M(₩44B)	US$20.7M(₩28.6B)

Revenue

FY2023US$149.9M
FY2024US$161.2M
FY2025US$186.8M

Operating profit

FY2023US$22.4M
FY2024US$26M
FY2025US$24.1M

Net income

FY2023US$20.4M
FY2024US$31.9M
FY2025US$20.7M

Key ratios (FY2025)

ROE

13.0%

Debt/Eq

44.3%

Op. margin

12.9%

Net margin

11.1%

Rev. YoY

▲ +15.9%

Why it matters

The company is classified as a mid-sized enterprise under Korean law, placing it in a regulatory tier between a small business and a large conglomerate.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?